A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients.

BACKGROUND: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.
METHODS: All medical records of the breast cancer patients taking LTZ with or without ANZ between 2004 and 2013 were reviewed. All patients were divided into two groups: the LTZ group included patients treated with LTZ alone, and the A-LTZ group included patients treated with ANZ who were automatically changed to LTZ due to change of the reimbursement policy.
RESULTS: From 359 cases, there were 179 cases in the LTZ group and 180 cases in the A-LTZ group. The mean age of patients in the LTZ group was 53.7 years and in the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took aromatase inhibitor monotherapy and 36.3% had a switching strategy, while in the A-LTZ group, 53.9% took AI monotherapy and 46.1% had a switching strategy. OS of the A-LTZ group was longer than that of the LTZ group.
CONCLUSION: The patients in A-LTZ, taking ANZ followed by LTZ had better OS than those in LTZ, taking LTZ alone.

Introduction

One of the standard treatments for estrogen receptor-positive breast cancer patients is endocrine therapy. It can be used as an adjuvant for the early stage1 or a palliative for the advanced disease.2 In Thailand, the available oral antiestrogen drugs include tamoxifen, anastrozole (ANZ), letrozole (LTZ), and exemestane. For premenopausal patients, tamoxifen seems to be the drug of choice, while aromatase inhibitors (AIs) have been used for postmenopausal patients.2–8 AIs are divided into two groups: nonsteroidal, which includes ANZ and LTZ, and steroidal, which includes exemestane. A switching strategy using an AI and tamoxifen is as effective as the AI monotherapy.9,10

In Thailand, some breast cancer patients receiving ANZ were automatically switched to LTZ due to the change of the reimbursement policy since 2008. We studied the outcome of this switching treatment to prove the noninferiority, but found that patients with ANZ followed by LTZ (A-LTZ) had better overall survival (OS) than patients with ANZ alone.11 Some studies have shown no difference in OS among AIs, either nonsteroidal or steroidal,12–17 some cases changed from ANZ to LTZ due to early adverse effect of ANZ, but no clear superiority of LTZ was demonstrated.7–10,17–21 One study showed LTZ seemed to be superior to ANZ, but no clear benefit was demonstrated.21 From our previous study,11 we could not conclude whether A-LTZ was superior or similar to LTZ. So we designed the study comparing patients receiving LTZ and patients receiving A-LTZ during the same period.

Materials and methods

All medical records of the breast cancer patients taking LTZ between 2004 and 2013 were reviewed. AI therapy included two types of strategy: AI monotherapy for 5 years; or 2–3 years of tamoxifen followed by 2–3 years of AI, up to total of 5 years. All collected patients were divided into two groups: the LTZ group included patients taking LTZ with or without tamoxifen; and the A-LTZ group included patients taking ANZ who were automatically changed to LTZ, either in an AI monotherapy strategy or AI-tamoxifen switching strategy, due to the change of the reimbursement policy. Demographic data, type of reimbursement, endocrine therapy, and OS were reviewed and analyzed.

Demographic data was analyzed using Excel® 2007 (Microsoft Corp, Redmond, WA, USA). Survival data was analyzed using Stata version 10.1 (StataCorp LP, College Station, TX, USA). OS was analyzed using a Cox regression model and presented as Kaplan–Meier estimates with hazard ratios (HR) and 95% confidence interval (CI). The LTZ and A-LTZ groups were compared using logrank test. A P-value <0.05 was considered statistically significant.

This study was reviewed and approved by the Khon Kaen University Ethics Committee for Human Research and was based on the Declaration of Helsinki and the International Conference on Harmonisation (ICH) Good Clinical Practice Guidelines.

Results

The medical records of 359 patients with invasive breast cancer treated with LTZ with or without ANZ were reviewed. There were 25 stage 1 patients (mean age 53.6±11.7 years), 202 stage 2 patients (mean age 53.8±9.9 years), 101 stage 3 patients (mean age 54.5±9.8 years), and 31 stage 4 patients (mean age 53.6±10.0 years). In 180 cases (50.1%) out of 359 cases, ANZ was replaced with LTZ. The mean age of the LTZ group was 53.7 years and of the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took AI monotherapy and 36.3% had a switching strategy, while among the A-LTZ patients, 53.9% took AI monotherapy and 46.1% had a switching strategy (Table 1). Within the A-LTZ group, the average duration of ANZ was 18.7 months. Stage 4 patients took the shortest duration of ANZ, of only 8.7 months, while stage 1 patients took the longest duration, of 24.2 months (Table 1).

Table 1

Comparison of demographic data between the LTZ and the A-LTZ groups of patients

Category	LTZ (n=179)	A-LTZ (n=180)
Mean age (years)	53.7±9.7	54.2±10.2
Clinical staging
• Stage 1	21 (11.73%)	4 (2.22%)
• Stage 2	86 (48.04%)	116 (64.44%)
• Stage 3	55 (30.73%)	46 (25.55%)
• Stage 4	17 (9.50%)	14 (7.77%)
Type of reimbursement
• CSMBS	89 (49.72%)	83 (46.11%)
• Non-CSMBS	90 (50.28%)	97 (53.89%)
Endocrine treatment strategy
• AI only	114 (63.69%)	97 (53.89%)
◦ Stage 1	18 (15.79%)	2 (2.06%)
◦ Stage 2	60 (52.63%)	59 (60.82%)
◦ Stage 3	32 (28.07%)	29 (29.90%)
◦ Stage 4	4 (3.51%)	7 (7.22%)
• AI + tamoxifen	65 (36.31%)	83 (46.11%)
◦ Stage 1	3 (4.62%)	2 (2.41%)
◦ Stage 2	26 (40.00%)	57 (68.67%)
◦ Stage 3	23 (35.38%)	17 (20.48%)
◦ Stage 4	13 (20.00%)	7 (8.43%)
Anastrozole duration (mean ± SD, months)
All		18.7±14.6
• Stage 1		24.2±18.6
• Stage 2		19.9±15.7
• Stage 3		18.4±14.4
• Stage 4		8.7±4.8

Abbrevations: AI, aromatase inhibitor; A-LTZ, anastrozole followed by letrozole; CSMBS, Civil Servant Medical Benefit Scheme (for government officers); LTZ, letrozole; SD, standard deviation.

The OS of breast cancer patients in the LTZ and A-LTZ groups was analyzed by Cox regression model and presented as Kaplan–Meier survival curve with a HR of 0.6824 (Figure 1), and the OS of the A-LTZ group was found to be significantly better than that of the LTZ group (P= 0.0386). When the OS was stratified by each stage (Table 2), only stage 4 patients in the A-LTZ group had a significantly better OS than stage-matched patients in the LTZ group (P=0.0114); the Kaplan–Meier survival curve was shown, with a HR of 0.3083, in Figure 2.

Figure 1

Kaplan–Meier survival curve of the LTZ and the A-LTZ groups of patients (all stages).

Abbreviations: A-LTZ, anastrozole followed by letrozole; LTZ, letrozole.

Table 2

Survival analysis between the LTZ and the A-LTZ groups of patients

Stage	Hazard ratio (95% confidence interval)	P-value
All	0.6824 (0.4741–0.9823)	0.0386*
1	–	0.3783
2	0.5885 (0.3226–1.0738)	0.0805
3	1.0618 (0.6063–1.8598)	0.8337
4	0.3083 (0.1180–0.8053)	0.0114*

Note:

Statistical significance.

Abbreviations: A-LTZ, anastrozole followed by letrozole; LTZ, letrozole.

Figure 2

Kaplan–Meier survival curve of stage 4 LTZ and A-LTZ patients.

Abbreviations: A-LTZ, anastrozole followed by letrozole; LTZ, letrozole.

Discussion

In Thailand, there are three major medical reimbursement systems: the Civil Servant Medical Benefit Scheme (CSMBS) for government officers, Social Security for employees, and Universal Coverage for all the remaining Thai people. On average, government officers have higher socioeconomic status than most Thai people. The proportions of CSMBS and non-CSMBS patients in the LTZ group (50:50) were higher than in the A-LTZ group (46:54). We classified the reimbursement systems into CSMBS and non-CSMBS because higher socioeconomic status might have a longer survival than lower socioeconomic status. In comparison, in our previous study,11 the proportions of CSMBS and non-CSMBS patients, respectively, in the ANZ group were nearly the same as those in the A-LTZ group (45:55 [ANZ] versus 46:54 [A-LTZ]). Although the OS of both the LTZ and ANZ groups differed significantly from the A-LTZ group, the HR of LTZ (0.6824) was higher than that of the ANZ (0.5515) group.

Some studies9,10,13,22 have reported the superiority of AI to tamoxifen but no significant difference in disease-free survival between the switching strategy compared with AI monotherapy strategy. However, AI produced more adverse events than tamoxifen, so we had to consider the survival benefit between the two strategies.19,22–24 The difference of HR between LTZ and ANZ groups might be affected by the proportions of AI monotherapy and switching strategy (64:36 versus 54:46).11

This study confirmed that treatment with A-LTZ should lengthen the survival of hormone-sensitive breast cancer patients better than LTZ or ANZ. The efficacy of LTZ was shown to be the same as ANZ in several studies,12–14 although some studies have shown LTZ might be superior to ANZ in terms of quality of life, due to lower incidence of adverse events.25,26 But there were no data about sequential therapy of ANZ and LTZ. Both drugs were classified in the same group – nonsteroidal AI. So it seemed to be irrational using both drugs sequentially, even with their different chemical structure.14 We observed the shortest duration of ANZ usage with narrowest standard deviation in stage 4 patients of the A-LTZ group, which might relate to statistical significance in the OS difference between the two groups. However, this retrospective study with small number of patients can reach limited conclusions. Further prospective study with larger number of patients should be performed to confirm the better outcome of sequential therapy of ANZ and LTZ.

Conclusion

The patients in the A-LTZ group, taking A-LTZ, seemed to have better OS than those in the LTZ group, taking LTZ alone.